文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽-1受体激动剂对高尿酸血症、血尿酸及痛风的影响:系统综述与荟萃分析

Effects of GLP‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-09

该系统综述与荟萃分析纳入18项随机对照试验共77942名参与者,评估肠促胰素治疗对血尿酸、痛风发作及高尿酸血症发生率的影响。结果显示肠促胰素治疗显著降低血尿酸(WMD −0.44 mg/dL,95%CI −0.52至−0.35)、减少痛风发作(HR 0.62,95%CI 0.53–0.72)及降低高尿酸血症发生率(OR 0.61,95%CI 0.53–0.70),体重减轻是血尿酸降低的显著调节因素,解释84.7%的试验间异质性。

要点

  • 肠促胰素治疗显著降低血尿酸(WMD −0.44 mg/dL,95%CI −0.52至−0.35)。
  • 肠促胰素治疗减少痛风发作(HR 0.62,95%CI 0.53–0.72)并降低高尿酸血症发生率(OR 0.61,95%CI 0.53–0.70)。
  • 体重减轻是血尿酸降低的显著调节因素,解释84.7%的试验间异质性。

核心结论

  • 肠促胰素治疗与血尿酸适度降低及痛风发作和高尿酸血症发生率降低相关,该效应主要与体重减轻有关。
  • 这些效应的临床相关性及任何不依赖体重成分的机制仍不确定,有待专门试验确认。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed/MEDLINE、Embase、CENTRAL和ClinicalTrials.gov至2026年7月,纳入疗程≥12周、报告血尿酸变化、痛风发作或高尿酸血症发生率的随机对照试验。
  • 共纳入18项随机对照试验,77942名参与者。
  • 采用随机效应荟萃分析、亚组分析、敏感性分析和荟萃回归,已在PROSPERO注册(CRD420261468511)。

主要发现

  • 与对照相比,肠促胰素治疗显著降低血尿酸(WMD −0.44 mg/dL,95%CI −0.52至−0.35)。
  • 肠促胰素治疗减少痛风发作(HR 0.62,95%CI 0.53–0.72)并降低高尿酸血症发生率(OR 0.61,95%CI 0.53–0.70)。
  • 双GIP/GLP-1受体激动剂(替尔泊肽)降低血尿酸幅度大于单GLP-1受体激动剂(−0.62 vs −0.35 mg/dL,p=0.001)。
  • 体重减轻是血尿酸降低的显著调节因素(β=−0.041 mg/dL每kg,p<0.001),解释84.7%的试验间异质性。
  • 存在显著的不依赖体重的截距(−0.19 mg/dL,p<0.001)。

关键数值与推荐

  • 血尿酸降低的GRADE证据确定性为高。
  • 痛风发作的GRADE证据确定性为中等(因小研究效应)。
  • 高尿酸血症发生率的GRADE证据确定性为中等。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 痛风发作的GRADE证据确定性为中等,因小研究效应。
  • 血尿酸降低及痛风发作和高尿酸血症发生率降低的临床相关性、不依赖体重成分的机制仍不确定,有待专门试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Objectives Hyperuricemia and gout are common but underappreciated comorbidities in Type 2 diabetes (T2D), obesity and chronic kidney disease (CKD). We aimed to quantify the pooled effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists on serum uric acid (SUA), incident gout and hyperuricemia, and to determine whether these effects vary by drug class and are mediated by weight loss. Methods We searched PubMed/MEDLINE, Embase, CENTRAL and ClinicalTrials.gov through July 2026 for RCTs of ≥ 12 weeks' duration reporting SUA change, gout flares or hyperuricemia incidence. Random-effects meta-analysis, subgroup and sensitivity analyses and meta-regression were performed. Registered with PROSPERO (CRD420261468511). Results Eighteen RCTs (77 942 participants) met inclusion criteria. Incretin-based therapy significantly reduced SUA versus control (weighted mean difference [WMD] −0.44 mg/dL, 95% CI −0.52 to −0.35), reduced incident gout flares (hazard ratio [HR] 0.62, 95% CI 0.53–0.72), and reduced hyperuricemia incidence (odds ratio [OR] 0.61, 95% CI 0.53–0.70). Dual GIP/GLP-1 RA (tirzepatide) produced greater SUA lowering than mono GLP-1 RAs (−0.62 vs. −0.35 mg/dL, p = 0.001). Body-weight loss was a significant moderator of SUA reduction (β = −0.041 mg/dL per kg, p < 0.001), explaining 84.7% of between-trial heterogeneity, with a significant weight-independent intercept (−0.19 mg/dL, p < 0.001). The SUA reduction was robust in all sensitivity analyses, including restriction to placebo-controlled trials. GRADE certainty was high for SUA and moderate for gout flares (owing to small-study effects) and hyperuricemia incidence. Conclusion Incretin-based therapies were associated with modest reductions in SUA and with a lower incidence of gout flares and hyperuricemia, an effect largely related to weight loss. The clinical relevance of these effects, and the mechanism of any weight-independent component, remains uncertain and warrant confirmation in dedicated trials.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Effects of GLP‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。